| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:30 | Kane Biotech Inc.: Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership | 1 | GlobeNewswire (USA) | ||
| 20.02. | Kane Biotech Inc (2): Kane publishes article in International Wound Journal | 3 | Stockwatch | ||
| 20.02. | Kane Biotech Inc.: Kane Biotech Announces Publication of revyve Wound Gel Article in the International Wound Journal | 1 | GlobeNewswire (USA) | ||
| KANE BIOTECH Aktie jetzt für 0€ handeln | |||||
| 19.02. | Kane Biotech Inc (2): Kane Biotech adds U.S. distributors for revyve products | 1 | Stockwatch | ||
| 19.02. | Kane Biotech Inc.: Kane Biotech Expands Commercial Activities in the United States | 686 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech" or the "Company") today announces that it has signed non-exclusive distribution/sales agreements... ► Artikel lesen | |
| 17.02. | Kane Biotech Inc (2): Kane Biotech passes regulatory "milestones" | 1 | Stockwatch | ||
| 17.02. | Kane Biotech Inc.: Kane Biotech Announces FDA 510(k) Clearance for revyve Antimicrobial Skin and Wound Cleanser | 469 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE) ("Kane Biotech". "Kane" or the "Company") today announces two regulatory milestones that strengthen the Company's... ► Artikel lesen | |
| 12.02. | Kane Biotech Inc (2): Kane Biotech revives commercial activity for revyve gel | 1 | Stockwatch | ||
| 12.02. | Kane Biotech Inc.: Kane Biotech Restarts Commercial Activities and Strengthens North American Management | 354 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech", "Kane" or the "Company") today announces the resumption of commercial activities in both the United... ► Artikel lesen | |
| 30.12.25 | Kane Biotech Inc (2): Kane Biotech 14-million-share private placement | 2 | Stockwatch | ||
| 18.12.25 | Kane Biotech Inc.: Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company | 1 | GlobeNewswire (USA) | ||
| 17.12.25 | Kane Biotech Inc.: Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 10.12.25 | Kane Biotech Inc.: Kane Biotech Receives Health Canada Approval for revyve Antimicrobial Wound Gel Spray | 1 | GlobeNewswire (USA) | ||
| 28.11.25 | Kane Biotech Inc (2): Kane Biotech loses $607,345 in Q3 2025 | 1 | Stockwatch | ||
| 28.11.25 | Kane Biotech Inc.: Kane Biotech Announces Third Quarter 2025 Financial Results | 718 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech", "Kane" or the "Company") today announced its third quarter 2025 financial results. Third Quarter... ► Artikel lesen | |
| 27.11.25 | Kane Biotech Inc (2): Kane Biotech arranges $800,000 private placement | 1 | Stockwatch | ||
| 27.11.25 | Kane Biotech Inc.: Kane Biotech Announces New Private Placement Offering | 2 | GlobeNewswire (USA) | ||
| 04.11.25 | Kane Biotech Inc (2): Kane receives clinical, preclinical data for revyve | 3 | Stockwatch | ||
| 17.09.25 | Kane Biotech Inc (2): Kane Biotech completes submission for wound cleanser | 1 | Stockwatch | ||
| 16.09.25 | Kane Biotech Inc.: Kane Biotech Completes U.S. FDA 510(k) Submission for revyve Antimicrobial Wound Cleanser | 284 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech" or the "Company") today announces that it has completed a U.S. Food and Drug Administration ("FDA")... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PAION | 0,061 | -21,54 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| NANOREPRO | 1,505 | -1,63 % | NanoRepro: "Kaltes Plasma stärkt die Haut" | NanoRepro setzt mit dem Marktstart ihres Kaltplasmageräts PHLAS ein strategisches Signal: Weg von einmaligen Sondereffekten, hin zu planbaren, margenstarken Erlösmodellen im Health- und Lifestyle-Segment.... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 22,990 | +14,89 % | Palatin Technologies, Inc.: Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Advancing differentiated MC4R-based obesity programs into clinical development
Melanocortin-based obesity therapies targeting rare MC4R pathway disorders with... ► Artikel lesen | |
| BRAIN BIOTECH | 2,490 | +6,87 % | HV-Termine: Hauptversammlungen bei All for One Group, BRAIN Biotech, LS Telcom, MeVis, MVV Energie, Novo Nordisk | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| AAP IMPLANTATE | 1,370 | -0,72 % | AAP Implantate AG - Struktur im Zwischenraum | ||
| CO.DON | 0,014 | -15,62 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| BIOXXMED | 1,150 | 0,00 % | PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH | DJ PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Heidelberg (pta000/09.03.2026/13:50... ► Artikel lesen | |
| CLINUVEL | 5,985 | +1,87 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL Investor Webinar Half Year Results December 2025 | ||
| SANGAMO THERAPEUTICS | 0,364 | +3,24 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally... ► Artikel lesen | |
| BIO-GATE | 0,510 | -7,27 % | Bio-Gate: EBITDA verbessert | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die Bio-Gate AG im ersten Halbjahr des Geschäftsjahres 2025 (per 31.12.) mit 3,44 Mio. Euro einen leicht unter Vorjahr... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,180 | +8,26 % | COSCIENS Biopharma Inc.: COSCIENS Provides Strategic Update | TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company") today announced that the Company has made a strategic decision... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| EDITAS MEDICINE | 2,240 | +12,87 % | Editas Medicine, Inc.: Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates | Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company's first-in-human clinical... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report |